NVDA+2.54%AAPL+1.32%GOOGL−1.62%MSFT+0.20%AMZN−0.10%TSM+1.60%SPCX+7.79%META+0.47%
StockVS

NASDAQ · Biotechnology · USD

Milestone Pharmaceuticals Inc. (MIST) Stock Analysis

Milestone Pharmaceuticals Inc. (MIST) is a Biotechnology stock listed on NASDAQ and quoted in US Dollar.

Last Updated: October 21, 2026

MIST

$0.70

−$0.02 (−3.23%)

Oct 21, 2026 · Market close

Compare

Price History

Hover for the daily close. The dotted line marks the period open.

Compare MIST with… →

MIST Key Statistics

As of Oct 21, 2026
Trading
Open
$0.72
Previous Close
$0.72
Day's Range
0.70–0.73
52-Week Range
0.70–3.06
Volume
669.86K
BetaHow much the share price moves relative to the wider market. 1.0 moves in line with it; above 1.0 swings more, below 1.0 less.
1.01
Valuation
Market Cap
$86.56M
P/E Ratio
unprofitable
P/S ratioMarket value divided by annual revenue. Useful for companies that are not yet profitable, where a P/E cannot be calculated.
36.95
EPS (ttm)Profit attributable to each share over the last twelve months.
−0.68
Financials (FY)
Revenue (FY)
$1.55M
Net Income (FY)
−$63.06M
Shares OutstandingThe total number of shares held by all investors. Market value is this figure multiplied by the share price.
124.50M
1-Year Return
−65.75%
Dividend and dates
Earnings Date
November 12, 2026
Avg Volume
1.42M

Only metrics the company reports are shown. Data provided by Yahoo Finance via yfinance. Updated daily.

Key facts

As of October 21, 2026, MIST closed at $0.70, −65.75% over 1 year.

Milestone Pharmaceuticals Inc. (MIST) has a market capitalization of $86.56M.

In fiscal 2025, MIST reported revenue of $1.55M.

MIST Stock Return by Calendar Year

Milestone Pharmaceuticals Inc. (MIST) return since May 2019: what $10,000 became

1 year
$10,000 $3,425
−65.75%
5 years
$10,000 $1,220
−87.80%
Since May 2019
$10,000 $452
−95.48%

If you had invested $10,000 in Milestone Pharmaceuticals Inc. (MIST) at the close on May 9, 2019, the earliest close on record here, it would have been worth $452 at the close on October 21, 2026: −95.48% in total, −33.99% a year, over a partial period shorter than 10 years. A historical calculation from closing prices adjusted for splits and dividends, before fees and taxes.

Calendar-year returns computed from daily closing prices. Partial years are shown muted and marked with an asterisk.

YearReturn
2026 (partial year)−65.58%
2025−14.41%
2024+41.32%
2023−57.83%
2022−39.54%
2021−2.24%
2020−58.15%
2019 (partial year)+4.16%

As of October 21, 2026.

MIST Revenue and Earnings by Fiscal Year

FY ends December
Fiscal yearRevenueNet incomeNet margin
2025$1.55M−$63.06M−4,078.8%
2024$0.00−$41.52M—
2023$1.00M−$59.69M−5,968.5%
2022$5.00M−$58.39M−1,167.8%
Fiscal yearRevenueGross profitOperating incomeNet incomeNet margin
2025$1.55M—−$62.14M−$63.06M−4,078.8%
2024$0.00—−$42.10M−$41.52M—
2023$1.00M—−$61.10M−$59.69M−5,968.5%
2022$5.00M—−$59.64M−$58.39M−1,167.8%

Annual figures as reported, in the company's reporting currency. As of December 31, 2025.

MIST Valuation vs Biotechnology Median

Median of 608 stocks
MetricMISTBiotechnology medianvs median
P/S ratio36.9513.30178% above

Medians across 608 Biotechnology stocks that report the metric. Medians, not averages, so one outlier cannot move them. As of October 21, 2026.

Recent News

All 12 articles ↓

News provided by third-party sources. Not financial advice.

Analysis

Data-derived

Company Overview

Milestone Pharmaceuticals Inc. (MIST) is capitalised at $86.56M on the latest close. The company sits in the Healthcare sector, in the Biotechnology industry. Headcount on file is 38.

The most recent close on file for MIST is $0.70, dated October 21, 2026. That is −$0.02 (−3.23%) against the previous close. The 52-week range on file runs from $0.70 to $3.06. The latest close sits 0.04% above that 52-week low.

Financial Health

In fiscal 2025, Milestone Pharmaceuticals Inc. reported revenue of $1.55M. The same year closed with a net loss of $63.06M. Earnings per share on a trailing basis come to −0.68.

Across the 4 fiscal years on file, revenue moves from $5.00M in 2022 to $1.55M in 2025. Of those 4 years, 0 report positive net income.

Valuation Assessment

The record shows negative trailing earnings, so no price-to-earnings ratio is published. The price-to-sales ratio is 36.95. On price-to-sales that is 177.82% above the Biotechnology median of 13.3. The medians here are taken across 608 Biotechnology companies that report the metric.

The trailing one-year total return is −65.75%. Across 5 years the annualized return works out at −34.35%. The reported beta is 1.01. Annualized volatility over the trailing 7 years is 104.74%.

Growth & Income

The record shows no dividend for MIST.

Across the complete calendar years on file, 2024 returned +41.32% and 2020 returned −58.15%. Of the 6 complete calendar years on file, 1 finished higher. So far in 2026 the total return is −65.58%.

Peer Comparison

Milestone Pharmaceuticals Inc. (MIST) operates in the Biotechnology industry. Here is how it compares to its closest peers by market capitalization:

Company Ticker Market Cap P/E Ratio
Milestone Pharmaceuticals Inc. MIST $86.56M —
Vertex Pharmaceuticals Incorporated VRTX $132.95B 30.4
Moderna, Inc. MRNA $98.14B —
Regeneron Pharmaceuticals, Inc. REGN $82.95B 19.9

The Biotechnology industry average P/E ratio is 16.6x. Milestone Pharmaceuticals Inc. has no P/E ratio because it is not currently profitable.

Every figure above is read from this page's own data on each daily rebuild. Informational only, not financial advice. As of October 21, 2026.

Related Biotechnology Stocks

VRTX

Vertex Pharmaceuticals Incorporated

$132.95B

 MRNA

Moderna, Inc.

$98.14B

 REGN

Regeneron Pharmaceuticals, Inc.

$82.95B

 ARGX

argenx SE

$55.97B

 ONC

BeOne Medicines AG

$43.97B

 RVMD

Revolution Medicines, Inc.

$41.64B
View all Biotechnology stocks →

Popular Healthcare Stocks

LLY

Eli Lilly and Company

$1.13T

 JNJ

Johnson & Johnson

$621.22B

 ABBV

AbbVie Inc.

$503.27B

 UNH

UnitedHealth Group Incorporated

$374.30B

 MRK

Merck & Co., Inc.

$369.78B
View all Healthcare stocks →

About Milestone Pharmaceuticals Inc.

Milestone Pharmaceuticals Inc., a biopharmaceutical company, focuses on the development and commercialization of cardiovascular medicines in the United States and Canada. It offers CARDAMYST (etripamil) nasal spray, a prescription medication for the conversion of acute symptomatic episodes of paroxysmal supraventricular tachycardia (PSVT) to sinus rhythm in adults. The company is also developing etripamil for the indication of atrial fibrillation with rapid ventricular rate (AFib-RVR). It has a license and collaboration agreement with Corxel Pharmaceuticals to develop and commercialize etripamil. Milestone Pharmaceuticals Inc.was incorporated in 2003 and is headquartered in Montreal, Canada.

Visit website →